Want to see IN:BROOKS full AI Analyst Report?

Brooks Laboratories Limited (BROOKS) Price & Analysis

2 Followers

BROOKS Stock Chart & Stats

₹62.75

-₹1.20(-1.88%)

At close: Jul 28 4:00 PM EDT

₹62.75

-₹1.20(-1.88%)

Day’s Range― - ―

52-Week Range₹36.50 - ₹165.95

Previous CloseN/A

Volume7.49K

Average Volume (3M)2.20K

Market Cap

₹1.73B

Enterprise Value₹1.98B

Total Cash (Recent Filing)₹75.49M

Total Debt (Recent Filing)₹85.17M

Price to Earnings (P/E)7.3

Beta1.67

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)8.35

Shares Outstanding29,457,249

10 Day Avg. Volume1,280

30 Day Avg. Volume2,199

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.89

Price to Sales (P/S)1.27

P/FCF Ratio21.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low leverage and a growing equity base give the company durable financial flexibility. This reduces refinancing and liquidity risk, supports continued R&D or capex, and allows management to weather revenue volatility without forcing asset sales or emergency funding.

Profitability ReboundA sharp swing to strong net margins and solid ROE indicates meaningful operational improvement and restored profitability. Sustained earnings power can fund reinvestment or deleveraging and signals that core operations can be profitable if revenue base stabilizes.

Improving Cash GenerationTransitioning from multi-year cash outflows to positive operating and free cash flow is a structural improvement. Even if conversion is imperfect, consistent positive cash flow reduces reliance on external financing and supports funding of working capital and strategic initiatives.

Bears Say

Sharp Revenue DeclineA material top-line drop undermines the sustainability of current margins and makes earnings more vulnerable to customer loss, pricing pressure, or volume declines. Until revenue trends stabilize, margin improvements may prove fragile and growth prospects limited.

Weak Cash ConversionA large gap between accounting profits and cash flow signals earnings quality issues, likely from working capital or receivables. This constrains the firm's ability to self-fund growth, dividends, or M&A, and raises the risk that earnings are less durable than reported.

Historic Earnings VolatilityThe company has a history of operating losses and volatile margins, evidencing inconsistent cost structure or pricing power. Such volatility increases execution risk for management and makes long-term forecasting, capital allocation, and investor confidence more difficult.

Brooks Laboratories Limited News

Brooks Laboratories Announces Strategic Merger of Joint Venture

Brooks Laboratories Limited ( ($IN:BROOKS) ) has shared an announcement. Brooks Laboratories Limited has announced a merger by...

10M ago

BROOKS FAQ

What was Brooks Laboratories Limited’s price range in the past 12 months?

Brooks Laboratories Limited lowest stock price was ₹36.50 and its highest was ₹165.95 in the past 12 months.

What is Brooks Laboratories Limited’s market cap?

Brooks Laboratories Limited’s market cap is ₹1.73B.

When is Brooks Laboratories Limited’s upcoming earnings report date?

Brooks Laboratories Limited’s upcoming earnings report date is Aug 07, 2026 which is in 5 days.

How were Brooks Laboratories Limited’s earnings last quarter?

Brooks Laboratories Limited released its earnings results on May 29, 2026. The company reported ₹0.52 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.52.

Is Brooks Laboratories Limited overvalued?

According to Wall Street analysts Brooks Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brooks Laboratories Limited pay dividends?

Brooks Laboratories Limited does not currently pay dividends.

What is Brooks Laboratories Limited’s EPS estimate?

Brooks Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brooks Laboratories Limited have?

Brooks Laboratories Limited has 29,457,249 shares outstanding.

What happened to Brooks Laboratories Limited’s price movement after its last earnings report?

Brooks Laboratories Limited reported an EPS of ₹0.52 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.998%.

Which hedge fund is a major shareholder of Brooks Laboratories Limited?

Currently, no hedge funds are holding shares in IN:BROOKS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology